Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen-Reference-Cited by-同舟云学术

Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen

Published:2023-05 Issue:5 Volume:61 Page:106771
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Scutari Rossana,Galli Laura^ORCID,Alteri Claudia,Poli Andrea,Piermatteo Lorenzo,Bigoloni Alba,Perno Carlo Federico,Lazzarin Adriano,Ceccherini-Silberstein Francesca,Castagna Antonella,Santoro Maria Mercedes^ORCID,Gianotti Nicola^ORCID

Funder

Gilead Sciences Inc

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference28 articles.

1. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Available at https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines (Accessed 21 September 2022).

2. Guidelines version 11.1,2022

3. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials;Cahn;J Acquir Immune Defic Syndr,2020

4. Brief report: Durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials;van Wyk;J Acquir Immune Defic Syndr,2020

5. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study